IDH-Mutant Gliomas: A Society for Neuro-Oncology Consensus Review on Diagnosis, Management, and Future Directions
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
Neuro-oncology 2022 Oct 12;[EPub Ahead of Print], JJ Miller, LN Gonzalez Castro, S McBrayer, M Weller, T Cloughesy, J Portnow, O Andronesi, JS Barnholtz-Sloan, BG Baumert, MS Berger, WL Bi, R Bindra, DP Cahill, SM Chang, JF Costello, C Horbinski, RY Huang, RB Jenkins, KL Ligon, IK Mellinghoff, LB Nabors, M Platten, DA Reardon, DD Shi, D Schiff, W Wick, H Yan, A von Deimling, M van den Bent, WG Kaelin, PY WenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.